Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Investigational ABC transporter inhibitors

    Access Status
    Fulltext not available
    Authors
    Falasca, Marco
    Linton, K.
    Date
    2012
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Falasca, M. and Linton, K. 2012. Investigational ABC transporter inhibitors. 21 (5): pp. 657-666.
    Source Title
    Expert Opinion on Investigational Drugs
    DOI
    10.1517/13543784.2012.679339
    ISSN
    1354-3784
    School
    School of Biomedical Sciences
    URI
    http://hdl.handle.net/20.500.11937/27166
    Collection
    • Curtin Research Publications
    Abstract

    Introduction: Multidrug resistance (MDR) is the main cause of failure in cancer therapy. One mechanism responsible for MDR is the active efflux of drugs by ATP-binding cassette (ABC) transporters. Several agents have been developed to block transporter-mediated drug efflux and some of these compounds have entered Phase II/III clinical testing. Evidence is also emerging of the role played by ABC transporters in cancer cell signalling that is likely to be important in disease progression and which is distinct from MDR. Areas covered: This article reviews current literature to analyse the rationale for targeting ABC transporters in cancer. Preclinical and clinical results of ABC transporter inhibitors in early clinical trials, as single agents or in combination with other drugs, are described. The development of new strategies to target MDR and the emerging roles of ABC transporters in cancer signalling are discussed. Expert opinion: The intense active search for safe and effective inhibitors of ABC transporters has led to some success in MDR reversal in preclinical studies. However, there has been little impact on clinical outcome. The discovery of novel, potent and nontoxic inhibitors as well as new treatment strategies is therefore needed. © 2012 Informa UK, Ltd.

    Related items

    Showing items related by title, author, creator and subject.

    • PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
      Serra, V.; Scaltriti, M.; Prudkin, L.; Eichhorn, Pieter ; Ibrahim, Y.H.; Chandarlapaty, S.; Markman, B.; Rodriguez, O.; Guzman, M.; Rodriguez, S.; Gili, M.; Russillo, M.; Parra, J.L.; Singh, S.; Arribas, J.; Rosen, N.; Baselga, J. (2011)
      There is a strong rationale to therapeutically target the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway in breast cancer since it is highly deregulated in this disease ...
    • Novel strategies for inhibiting cancer growth
      Schaefer, Rainer (2008)
      At present, most cancers are treated with surgery, radiotherapy and chemotherapy, used alone or in combination. Surgery and radiotherapy are the primary treatment modalities after early detection of cancers and they ...
    • ABC transporters as cancer drivers: Potential functions in cancer development
      Domenichini, Alice; Adamska, A.; Falasca, Marco (2019)
      © 2018 Elsevier B.V. Background: ABC transporters have attracted considerable attention for their function as drug transporters in a broad range of tumours and are therefore considered as major players in cancer ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.